Phenoxybenzamine in the management of neurogenic vesical dysfunction.
The clinical effect of phenoxybenzamine, an alpha blocking agent, was studied in a series of 37 patients with varying degrees of neurogenic vesical dysfunction. An over-all 78 per cent success rate was achieved, with an 86 per cent success rate in patients with reflex neurogenic bladder. Phenoxybenzamine demonstrates excellent results in patients with neurovesical dysnfunction who are unable to empty their bladders by other means. The drug demonstrated effectiveness regardless of the level of the lesion, cystometric findings or duration of neurogenic vesical disease.
D000293:Adolescent; D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010643:Phenoxybenzamine / Q000627:therapeutic use*; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy*
D010643:Phenoxybenzamine